South Wales Evening Post

New Covid-19 vaccine ‘will be used in Wales’

- CATHY OWEN Reporter cathy.owen@walesonlin­e.co.uk

FIRST Minister Mark Drakeford has confirmed that a new Covid vaccine will be used in Wales. The vaccine, which has been developed by Valneva, has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency (MHRA).

The independen­t medicines regulator is the first in the world to approve the Valneva product, MHRA said in a statement. The drug has been approved for use in people aged 18 to 50, with two doses to be taken 28 days apart.

It can also be stored at a normal fridge temperatur­e. The jab developed by the firm, which has a factory in Livingston near Edinburgh, is the sixth Covid-19 vaccine to be granted an MHRA authorisat­ion.

Yesterday Mr Drakeford confirmed to BBC Radio Wales: “It will be available to us in Wales, and vaccinatio­n remains the single most important thing that any one of us can do in our own lives to protect ourselves and to protect other people.

“Having another vaccine available just makes the system more resilient, and it is good news for Wales.”

The vaccine is the first wholevirus inactivate­d one to gain regulatory approval in the UK. With this type of vaccine, the MHRA says the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body but can still trigger an immune response to the Covid-19 virus. This process is widely used already in the production of flu and polio vaccines.

Dr June Raine, MHRA Chief Executive, said: “Our approval of the Covid-19 vaccine made by Valneva today follows a rigorous review of the safety, quality and effectiven­ess of this vaccine, and expert advice from the government’s independen­t scientific advisory body, the Commission on Human Medicines.”

Professor Sir Munir Pirmohamed, Chair of the independen­t Commission on Human Medicines, said: “The independen­t Commission on Human Medicines and its Covid-19 Expert Working Group has carefully considered the available evidence and are pleased to say that we have advised that the benefit risk balance is positive.

“The vaccine is approved for use in people aged 18 to 50 years, with the first and second doses to be taken at least 28 days apart.

“Each type of vaccine has a different pattern of antibody response over time. For the Valneva vaccine, two doses are required before a robust antibody response is raised.

This means that people will need to be made aware that protection will only start after two doses.

“The storage temperatur­e for the Valneva vaccine – of 2 degrees C to 8 degrees C – is similar to that of a domestic fridge, making it appropriat­e for use in countries where storage at very low temperatur­es is not possible.”

The news comes as the number of deaths involving coronaviru­s registered each week in England and Wales continues to rise, although levels remain well below those reached during previous waves of the virus.

The NHS Confederat­ion has said very high rates of Covid-19 infections are having a “major impact” on the health service, which is facing pressures it would see in a “bad winter” well into spring.

But Downing Street has rejected the call to reintroduc­e greater mask-wearing and a push to encourage mixing outdoors, and the latest lockdown review in Wales announced yesterday has seen little change. The legal requiremen­t to wear face coverings in health and social care settings will remain in place for another three weeks.

However a rule that means businesses have to carry out specific coronaviru­s risk assessment­s will end on Monday.

The UK had been due to receive 100 million doses of the French firm’s jab, but the UK Government cancelled the deal in September due to a “breach of obligation­s”.

The former chairwoman of the country’s vaccine taskforce last year said UK Government may have “acted in bad faith” in the way it cancelled the deal for the Valneva vaccine.

Dame Kate Bingham, who stood down from her role at the end of 2020, criticised the decision to pull out of the agreement before Valneva had finished clinical testing of the vaccine.

The decision was not only a blow to internatio­nal pandemic efforts, but would dampen the UK’S resilience to future disease outbreaks, Dame Kate said in a speech at Oxford University in November.

Having another vaccine available just makes the system more resilient, and it is good news for Wales First Minister Mark Drakeford

 ?? POOL ?? Scotland’s First Minister Nicola Sturgeon operates a cell expansion Bioreactor during a visit to the new Valvena Scotland vaccine manufactur­ing plant in Livingston, Scotland.
POOL Scotland’s First Minister Nicola Sturgeon operates a cell expansion Bioreactor during a visit to the new Valvena Scotland vaccine manufactur­ing plant in Livingston, Scotland.

Newspapers in English

Newspapers from United Kingdom